Hanyu Medical, a Chinese startup that develops heart valve interventional medical devices, has garnered 500 million yuan ($72 million) in its Series D round to promote the premarket clinical trials of what could be China’s first domestically developed mitral valve repair product.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
